12:00 AM
Jan 28, 2013
 |  BC Week In Review  |  Company News  |  Deals

Amunix Inc., J&J deal

Amunix partnered with Johnson & Johnson's Janssen Biotech Inc. subsidiary to develop up to three fusion proteins by combining Amunix's XTEN half-life...

Read the full 89 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >